Written by Klarity Editorial Team
Published: Jun 1, 2026

Finding the right mental health support has never been more important—or more complex. The telehealth landscape has transformed dramatically over the past few years, with some providers expanding their services while others have shut down or faced serious legal challenges. If you’re considering online mental health care in 2025, understanding which platforms are still operating, what medications they prescribe, and how they compare can save you time, money, and frustration.
This comprehensive guide breaks down everything you need to know about today’s top telehealth mental health providers, from ADHD treatment to anxiety management, and helps you make an informed decision about your care.
The mental health telehealth industry has undergone significant upheaval. What was once a rapidly expanding market filled with promise has matured into a more cautious, regulated space where patient safety and quality care take precedence over convenience alone.
Major industry shifts include:
These changes mean patients now face a more fragmented landscape where not all providers can treat all conditions—particularly ADHD, anxiety disorders requiring controlled medications, and insomnia.
Understanding which platforms are active, what they treat, and what they can prescribe is crucial for finding the right fit for your needs.
Talkiatry remains one of the most comprehensive options for serious mental health concerns. Unlike direct-to-consumer apps, Talkiatry employs fully licensed psychiatrists who can diagnose and treat the full spectrum of mental health conditions, including prescribing controlled substances when medically appropriate.
Talkiatry’s strength lies in its medical rigor and insurance integration, though some patients report longer wait times for initial appointments (1-3 weeks) and occasional provider changes due to network adjustments.
Brightside focuses exclusively on depression, anxiety, PTSD, OCD, and insomnia—but explicitly does not treat ADHD. The platform takes a conservative medication approach, refusing to prescribe any controlled substances.
Brightside works well for patients seeking straightforward depression or anxiety treatment with SSRIs or similar medications, but it’s not suitable for those needing ADHD care or controlled anxiety medications.
Cerebral has dramatically scaled back operations after 2022’s regulatory challenges. While still operational, the platform now takes an extremely conservative approach to prescribing.
Existing ADHD patients on stimulants were gradually transitioned to alternative providers or medications. The platform’s rocky history and subscription model (which some users find difficult to cancel) make it a less attractive option compared to newer alternatives.
Teladoc, MDLive, and Amwell serve millions of patients for urgent care, primary care, and basic mental health needs. However, all three have strict policies against prescribing controlled substances via telehealth.
Common limitations across all three:
These platforms excel at treating mild to moderate depression and anxiety with standard antidepressants, providing therapy referrals, and handling non-controlled medication refills. They’re often covered fully by employer health plans, making them cost-effective for basic needs. However, patients with ADHD, treatment-resistant anxiety, or insomnia requiring sleep aids will need to seek specialized psychiatric care elsewhere.
PlushCare offers primary care with mental health services but maintains similarly strict policies:
PlushCare stands out for integrated primary care alongside mental health treatment, making it suitable for patients managing multiple health concerns with one provider.
Hims & Hers has carved out a unique niche focusing on lifestyle wellness, including mental health, hair loss, sexual health, and weight management.
Hims & Hers doesn’t prescribe controlled substances but excels at providing accessible care for common concerns like mild anxiety or depression, while also addressing related health goals like weight management that traditional mental health platforms ignore.
The ADHD telehealth landscape changed dramatically after regulatory crackdowns in 2022-2024. Here’s what you need to know:
The reality: If you need ADHD medication management via telehealth in 2025, your viable options are primarily insurance-based psychiatric services like Talkiatry or regional telepsychiatry networks. The direct-to-consumer ‘easy ADHD meds’ era has ended due to widespread abuse and regulatory intervention.
What about non-stimulant ADHD medications? Some platforms will prescribe Strattera (atomoxetine), Qelbree (viloxazine), or Intuniv (guanfacine)—non-controlled ADHD medications. However, these are generally less effective than stimulants for many patients and come with their own side effect profiles.
The dramatic differences in prescribing policies stem from a combination of federal regulations, state laws, corporate risk management, and the fallout from Done and Cerebral’s legal troubles.
The Ryan Haight Act normally requires an in-person medical evaluation before prescribing controlled substances. During COVID-19, the DEA granted temporary flexibilities allowing tele-prescribing without in-person visits. This waiver has been extended through December 2025, but its future is uncertain.
This uncertainty has made many telehealth companies risk-averse. Rather than potentially violating federal law if the waiver ends, they’ve simply prohibited controlled substance prescribing altogether.
Business liability concerns also play a role. After Done’s executives were criminally charged and Cerebral paid millions in penalties, many platforms decided that avoiding controlled substances entirely was safer than implementing rigorous prescribing safeguards.
Millions of Americans legitimately need medications like:
The one-size-fits-all ‘no controlled substances’ policies leave these patients with few options: seek in-person psychiatry (often with months-long wait lists), try platforms like Talkiatry that still prescribe responsibly, or go without needed treatment.
Understanding the gaps in the current telehealth market reveals where platforms like Klarity Health can provide genuine value.
Responsible controlled substance prescribing: Unlike general telehealth platforms that refuse all controlled medications, Klarity providers can prescribe stimulants, benzodiazepines, and other controlled substances when medically appropriate—following proper evaluation protocols and ongoing monitoring.
No subscription required: While competitors like Cerebral and Brightside lock patients into monthly subscriptions (often $99-$365/month), Klarity uses straightforward per-visit pricing. You pay for what you need, when you need it.
Fast appointment availability: Where insurance-based platforms like Talkiatry may have 1-3 week waits, Klarity typically offers appointments within days, addressing the urgency many people feel when seeking mental health care.
Dual insurance and cash-pay options: Klarity accepts many insurance plans while also offering transparent cash-pay rates, giving patients flexibility based on their coverage and financial situation.
Comprehensive condition coverage: From ADHD and anxiety to insomnia, PMDD, and binge eating disorder, Klarity treats conditions that other platforms either won’t touch or require multiple separate services to address.
Think of Klarity as occupying the middle ground between Done’s reckless over-prescribing (which rightfully drew regulatory action) and Teladoc’s overly cautious refusal to prescribe anything controlled (which leaves many patients underserved).
For patients who:
Klarity offers:
Most major telehealth platforms now operate nationwide or near-nationwide, but some restrictions remain:
All currently operating platforms discussed in this guide serve these six high-population states:
Talkiatry operates in 43 states but notably excludes some smaller markets. Check their website for current coverage in your state.
These platforms are no longer operating anywhere:
Understanding the true cost of telehealth mental health services requires looking beyond advertised prices to consider insurance coverage, subscription commitments, and medication costs.
Cerebral:
Brightside:
Hims & Hers:
Talkiatry:
PlushCare:
General Telehealth (Teladoc, MDLive, Amwell):
Klarity Health:
For ongoing monthly care, subscription models may seem convenient, but consider:
Three-month cost comparison (assuming monthly check-ins):
| Provider | Subscription Model | Insurance Impact | 3-Month Total |
|---|---|---|---|
| Cerebral | $99 × 3 = $297 | Limited | ~$297 |
| Brightside | $95 × 3 = $285 | Often covered | $0-285 |
| Hims & Hers | $85 × 3 = $255 | Not accepted | $255 |
| Talkiatry | Per-visit | Usually covered | $75-150 |
| Klarity | $149 + $59 + $59 = $267 | Accepted | $0-267 |
For stable patients needing quarterly check-ins:
| Provider | Quarterly Cost |
|---|---|
| Cerebral | $297 (billed monthly even without visits) |
| Klarity | $59 (one follow-up only) |
The flexibility of pay-per-visit pricing becomes especially valuable for patients whose needs vary month-to-month or who achieve stability and need less frequent monitoring.
Insurance tip: Even with ‘in-network’ telehealth, verify your specific plan’s coverage for psychiatry or therapy services. Some plans cover medical telehealth fully but apply different rules for mental health care, requiring copays or coinsurance.
The collapse of Done and scaling back of Cerebral offer important lessons for patients evaluating telehealth providers:
Done’s alleged practice of pressuring providers to prescribe to meet quotas and conducting cursory evaluations represents exactly what patients should avoid. The company’s downfall—with executives facing criminal charges—validates concerns about platforms prioritizing growth over patient safety.
The extension of COVID-era prescribing flexibilities through December 2025 provides temporary certainty, but the long-term future remains unclear. Potential scenarios include:
Full return to pre-COVID rules: Requiring in-person visits before prescribing controlled substances would devastate current telehealth models and force hybrid approaches.
Permanent modified flexibilities: Allowing tele-prescribing of some controlled substances (like ADHD medications) with enhanced safeguards, while requiring in-person visits for higher-risk drugs.
State-by-state variations: Some states may allow broader telehealth prescribing than federal baseline.
Consolidation continues: Expect more mergers between telehealth platforms and traditional healthcare systems. CVS, Optum, and other healthcare giants are acquiring or partnering with telehealth startups.
Integration with in-person care: Hybrid models combining video visits with occasional in-person check-ups will likely become standard, especially for patients on controlled substances.
Expanded scope: Mental health platforms increasingly address related conditions like weight management, metabolic health, and sleep disorders as patients seek comprehensive wellness solutions rather than single-condition treatment.
AI-assisted care: Some platforms are experimenting with AI-supported triage, symptom tracking, and treatment recommendations (though prescribing decisions still require human clinicians).
Klarity’s approach balances accessibility with responsibility—offering comprehensive psychiatric care including controlled substances when appropriate, without the rushed, quota-driven problems that brought down Done or the overcautious restrictions that limit general telehealth platforms.
Comprehensive platforms like Klarity Health typically conduct 30-45 minute initial psychiatric evaluations covering:
This thoroughness matters. Quick 10-15 minute evaluations that led to Done’s problems don’t allow proper diagnosis or treatment planning. Quality platforms invest time upfront to ensure accurate diagnosis and appropriate treatment.
The telehealth mental health industry’s turbulent few years have ultimately benefited patients by weeding out irresponsible providers and establishing clearer standards. While you have fewer options today than in 2021, the remaining platforms generally offer better, safer care.
The key takeaways:
For many patients seeking comprehensive psychiatric care including responsible controlled substance prescribing, transparent pricing, and fast availability, platforms like Klarity Health fill a crucial gap between overly restrictive general telehealth and the now-defunct quick-script services.
Mental health care is too important to leave to chance. Take time to research your options, verify each platform’s prescribing policies and limitations, and choose a provider that prioritizes your long-term wellbeing over convenience or profit.
Ready to get started with quality psychiatric care? Klarity Health offers comprehensive mental health treatment with board-certified providers who can address ADHD, anxiety, depression, insomnia, and more—often with appointments available within days. Whether you’re paying with insurance or out-of-pocket, you’ll find transparent pricing and genuine support for your mental health journey.
Visit Klarity Health to schedule your initial evaluation and take the first step toward better mental health with a platform designed to address the gaps left by today’s fragmented telehealth landscape.
AP News – ‘Top executives of California-based telehealth company Done charged with distributing Adderall’ (apnews.com) – June 14, 2024
TIME Magazine – ‘Why the Telehealth Industry Is in Turmoil’ (time.com) – November 1, 2022
TechTarget – ‘Pushing ADHD telehealth prescriptions costs Cerebral millions’ (www.techtarget.com) – November 6, 2024
Brightside Health – ‘What medications do we prescribe?’ Official FAQ (www.brightside.com) – Updated 2025
Teladoc Health – ‘Prescription Policy Information’ Official Policy (www.teladochealth.com) – Updated 2023
Find the right provider for your needs — select your state to find expert care near you.